-
Morning Market Losers
Monday, July 18, 2011 - 10:02am | 108Nabi Biopharmaceuticals (NASDAQ: NABI) dipped 69.27% to $1.73 at 9:55 am. NABI reported that NicVAX (Nicotine Conjugate Immunotherapeutic) failed to meet its primary endpoint in the company's first of two confirmatory Phase III clinical trials. WebMD Health Corp (NASDAQ: WBMD) fell 29.24% to $32....
-
UPDATE: MLV Lowers PT on Peregrine Pharmaceuticals to $8.50
Monday, July 18, 2011 - 9:39am | 95MLV is out with its report today on Peregrine Pharmaceuticals (NASDAQ: PPHM), lowering its PT from $10 to $8.50. In a note to clients, MLV writes, "In our view, Peregrine has made considerable progress in advancing its pipeline and several major catalysts are approaching, however delays have led...
-
Nabi Biopharmaceuticals Announces Results of First NicVAX Phase III Clinical Trial; Drug Did not Meet Primary Endpoint
Monday, July 18, 2011 - 9:05am | 75Nabi Biopharmaceuticals (Nasdaq: NABI) today announced that NicVAX did not meet its primary endpoint in the company's first of two confirmatory Phase III clinical trials. A preliminary assessment of the trial data showed that subjects treated with NicVAX quit smoking at a similar rate of...
-
Piper Jaffray Maintains Overweight on Amgen
Monday, July 18, 2011 - 9:00am | 76Piper Jaffray is out with its report today on Amgen (NASDAQ: AMGN), maintaining Overweight. In a note to clients, Piper Jaffray writes, "We believe Amgen's legacy products will remain a source of concern until denosumab sales exceed expectations. We look for upside in 2Q11 Xgeva sales and AMG785...
-
LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark
Monday, July 18, 2011 - 8:30am | 123Laboratory Corporation of America® Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on August 12, 2011, LabCorp's previously announced cash tender offer for all outstanding shares of the common stock of Orchid Cellmark Inc. (NASDAQ: ORCH). On May...
-
Synageva BioPharma and Trimeris Announce Filing of S-4 Registration Statement Regarding the Previously Announced Merger
Monday, July 18, 2011 - 8:15am | 105Synageva BioPharma Corp. and Trimeris, Inc. (NASDAQ: TRMS) announced today that Trimeris has filed a Form S-4 Registration Statement with the U.S. Securities and Exchange Commission pertaining to the previously announced merger of Trimeris and Synageva. The Registration Statement has not yet been...
-
Bionovo Announces Publication of Bezielle™ Effect on Metabolic Fluxes in Breast Cancer
Monday, July 18, 2011 - 8:05am | 134Bionovo, Inc. (NASDAQ: BNVI) today announced the publication of a study of the metabolic effects of its drug candidate, Bezielle, on cancer cells in the International Journal of Cancer. "This study confirms and expands our earlier understanding of the mechanism of Bezielle cell killing effect,"...
-
Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming ESGO Meeting
Monday, July 18, 2011 - 7:32am | 102Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology to be held September 11...
-
Bank of America Comments on Gilead Sciences After Research Results
Monday, July 18, 2011 - 7:11am | 214Bank of America has published a report on Gilead Sciences (NASDAQ: GILD) after HIV medication research results. In the report, Bank of America comments, "Our $43 price objective is based on 9.6x our 2012 non-GAAP EPS estimate and we believe pressures on the base business (U.S. and EU) will keep...
-
Cyclacel Pharmaceuticals Amends Its Sapacitabine License Agreement With Daiichi-Sankyo
Monday, July 18, 2011 - 7:01am | 63Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), today announced that effective July 11, 2011, Cyclacel Limited, a wholly-owned subsidiary of the Company, entered into an amendment of its license agreement, dated September 10, 2003 between Cyclacel Limited and Daiichi Sankyo Company, Limited relating...
-
Citi Reiterates Hold and PT of $36 on Dendreon
Monday, July 18, 2011 - 6:50am | 46Citi reiterated its Hold rating on Dendreon (NASDAQ: DNDN). At the same time, the rating agency left its price target on the company's stock unchanged at $36. On Friday, Dendreon lost 0.87% of its value to finish the week at $38.80.
-
Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting
Friday, July 15, 2011 - 4:15pm | 71Transition Therapeutics (Nasdaq: TTHI) announced today that data from the Phase 2 clinical trial of ELND005 in mild to moderate Alzheimer's disease patients will be presented at the International Conference on Alzheimer's Disease meeting, to be held July 16-21, 2011 in Paris, France. There will be...
-
Rodman & Renshaw Reiterates Vical Market Outperform, $6 PT
Friday, July 15, 2011 - 12:32pm | 101Rodman & Renshaw reiterated its Vical (NASDAQ: VICL) Market Outperform rating and $6 price target in a research report published today. In the report, Rodman & Renshaw states, "We are reiterating our Market Outperform / Speculative Risk rating for Vical and our 12-month target price of $6...
-
Interview with Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. Discusses the Potential of Future Partners or Acquisition
Friday, July 15, 2011 - 12:16pm | 1783Point Roberts, WA, LINCOLNSHIRE, Ill – July 15, 2011 –(Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview with Mr. Stephen M. Simes, President and Chief Executive...
-
NASDAQ Top Percentage Gainers: Omega Navigation, Icagen, Universal Forest, Gulf Resources
Friday, July 15, 2011 - 11:37am | 500POINT ROBERTS - July 15, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for July 14, 2011. Omega Navigation Enterprises, Inc topped the gainer list, rising about 46% on Thursday. Omega Navigation...